IMCRMEDIUM SIGNALOPERATIONAL10-K

IMCR shows strong revenue growth and improved losses but experienced a significant deterioration in operating cash flow, turning from positive $26.1M to negative $10.7M.

The company is successfully expanding KIMMTRAK's commercial reach with 43% revenue growth and meaningful improvements in operating and net losses, indicating growing market adoption. However, the dramatic swing in operating cash flow from positive to negative raises questions about working capital management and the sustainability of current operations despite top-line growth.

Comparing 2026-02-25 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

IMCR delivered strong operational progress with revenue jumping 43% to $249.4M while cutting operating losses by 36% and net losses by 31%, demonstrating improving unit economics. However, operating cash flow deteriorated sharply from +$26.1M to -$10.7M, likely driven by increased working capital needs as evidenced by higher accounts receivable (+21%) and inventory (+23.8%). The mixed picture shows a company scaling successfully but facing cash management challenges that investors should monitor closely.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-141.1%
$26.1M-$10.7M

Operating cash flow fell 141.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Revenue
P&L
+43.1%
$174.4M$249.4M

Strong top-line growth of 43.1% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
+35.6%
-$70.5M-$45.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+30.5%
-$51.1M-$35.5M

Net income grew 30.5% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
+23.8%
$5.4M$6.7M

Inventory built 23.8% — monitor whether demand supports this build or if write-downs may follow.

R&D Expense
P&L
+23.7%
$222.2M$274.9M

R&D investment increased 23.7% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+21%
$52.1M$63.0M

Receivables grew 21% — monitor days sales outstanding for collection efficiency.

Current Liabilities
Balance Sheet
+16.3%
$212.2M$246.7M

Current liabilities rose 16.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-26
ADDED
o Yes x No The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of the registrant, based upon $31.38, the closing price of the registrant s American Depositary Shares on the Nasdaq Global Market on June 30 2025 (the last business day of the registrant s most recently completed second fiscal quarter) was approximately $ 1.5 billion .
As of January 31, 2026 , the registrant had 50,695,078 ordinary shares (including ordinary shares in the form of American Depositary Shares) outstanding, par value 0.002, shares consisting of 49,960,681 voting ordinary shares and 734,397 non-voting ordinary shares.
We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop.
KIMMTRAK is now approved in 39 countries and the Company has commercially launched the product in 30 countries, including the United States, Germany and France, among other territories.
To support our commercialization efforts, we have an exclusive multi-regional collaboration with Medison Pharma Ltd.
+7 more — sign up free →
REMOVED
o Yes x No The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of the registrant, based upon $33.89, the closing price of the registrant s American Depositary Shares on the Nasdaq Global Market on June 28, 2024 (the last business day of the registrant s most recently completed second fiscal quarter) was approximately $ 1.6 billion .
As of January 31, 2025 , the registrant had 50,068,126 ordinary shares (including ordinary shares in the form of American Depositary Shares) outstanding, par value 0.002, shares consisting of (i) 49,333,729 voting ordinary shares and 734,397 non-voting ordinary shares.
We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop after KIMMTRAK in mUM.
KIMMTRAK is now approved in 39 countries for the treatment of unresectable or mUM.
In 2024, we launched KIMMTRAK in 14 additional countries (including Australia, Spain, Poland, and the United Kingdom excluding Scotland, and, reached price agreements with England's National Institute for Clinical Excellence ("NICE"), with further commercial launches planned in additional territories where KIMMTRAK is approved.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →